COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM BASAL INSULIN plus ORAL ANTIDIABETICS-GLP1-RA TO IDEGLIRA IN BRAZIL

被引：0

作者：

de Almeida, V ^{[1
]}

Leonart, L. P. ^{[2
]}

Tonin, F. ^{[2
]}

Izar Helfenstein Fonseca, M. ^{[1
]}

Miyamoto Fortes, E. ^{[1
]}

Melo, T. ^{[3
]}

Pititto, L. ^{[1
]}

Gaspar, A. ^{[3
]}

Krakauer, M. ^{[4
]}

机构：

[1] Novo Nordisk, Sao Paulo, SP, Brazil

[2] Heads Hlth, Curitiba, Parana, Brazil

[3] Heads Hlth, Sao Paulo, Brazil

[4] Fac Med ABC, Santo Andre, SP, Brazil

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 07期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE295

引用

页码：S391 / S391

页数：1

共 50 条

[31] COST-EFFECTIVENESS OF SWITCHING TO INSULIN ASPART FROM HUMAN SOLUBLE INSULIN IN CHINESE PATIENTS WITH TYPE-2 DIABETES ON A BASAL-BOLUS REGIMEN
Ji, Q. H.
Ye, Q.
Zhang, Y. Z.
VALUE IN HEALTH, 2013, 16 (03) : A164 - A165
[32] Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Virginia Valentine
Jennifer Goldman
Jay H. Shubrook
Diabetes Therapy, 2017, 8 : 739 - 752
[33] Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
Valentine, Virginia
Goldman, Jennifer
Shubrook, Jay H.
DIABETES THERAPY, 2017, 8 (04) : 739 - 752
[34] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Schmidt, I
Wittrup-Jensen, KW
DIABETES, 2004, 53 : A288 - A288
[35] Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
McCrimmon, Rory J.
Falla, Edel
Sha, Jo Zhou
Alsaleh, Abdul Jabbar Omar
Lew, Elisheva
Hudson, Richard
Baxter, Mike
Palmer, Karen
DIABETES THERAPY, 2021, 12 (12) : 3217 - 3230
[36] Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
Rory J. McCrimmon
Edel Falla
Jo Zhou Sha
Abdul Jabbar Omar Alsaleh
Elisheva Lew
Richard Hudson
Mike Baxter
Karen Palmer
Diabetes Therapy, 2021, 12 : 3217 - 3230
[37] In Insulin-Naive Patients with T2DM Uncontrolled on GLP-1 Receptor Agonists (GLP-1RA), IDegLira (Novel Combination of Insulin Degludec plus Liraglutide) Resulted in Improved Patient-Reported Outcomes vs. Unchanged GLP-1RA
Linjawi, Sultan
Brod, Meryl
Bode, Bruce W.
Chaykin, Louis B.
Courreges, Jeanpierre
Handelsman, Yehuda
Kongso, Jens Harald
Reiter, PanagIota Diamantopoulou
Simpson, Richard W.
DIABETES, 2015, 64 : A296 - A296
[38] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
DIABETOLOGIA, 2004, 47 : A344 - A344
[39] Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
Barnaby Hunt
Divina Glah
Maarten van der Vliet
Diabetes Therapy, 2017, 8 : 753 - 765
[40] Cost-Effectiveness Analysis of Influenza A (H1N1) Chemoprophylaxis in Brazil
Vecoso, Luisa von Zuben
Silva, Marcus Tolentino
Resende, Mariangela Ribeiro
da Silva, Everton Nunes
Galvao, Tais Freire
FRONTIERS IN PHARMACOLOGY, 2019, 10

← 1 2 3 4 5 →